FDNA to Exhibit at the 2014 ACMG Meeting and Present the Facial Dysmorphology Novel Analysis Technology
FDNA will unveil Face2Gene™, a mobile app for research and investigation of genetic syndromes, using facial photos.
(PRWEB) March 13, 2014
FDNA® (http://www.fdna.com) – a pioneer in computer-aided dysmorphology analysis is scheduled to exhibit at the 2014 ACMG meeting, booth #915 in Nashville, Tennessee. The company will present its proprietary technology in a scheduled theater presentation and unveil Face2Gene, the first available search and reference mobile application, powered by this premier technology. FDNA’s technology facilitates detection of facial dysmorphic features and recognizable patterns of human malformations, while accessing comprehensive and up-to-date genetic references. Face2Gene will aid and empower medical professionals in accelerating and increasing confidence in the research and investigation of genetic syndromes.
"FDNA’s game-changing technology introduces an objective computer-aided dimension to the “art of dysmorphology,” transforming the analysis into an evidence-based science." Dr. Michael R. Hayden, CM, OBC, FRSC – Chairman of FDNA’s Scientific Advisory Board & Steering Committee and Editor in Chief of Clinical Genetics.
FDNA will present its cutting edge technology and solution during a theatre presentation titled “Incorporating Computer Aided Facial Analysis into Clinical Practice, FDNA – Accessible Genetics” on Friday March 28, 2014. Speakers will include Dr. Lynne M. Bird, MD, FACMG from the University of California in San Diego; Prof. Lior Wolf, PhD, Chief Scientific Advisor & Co-founder of FDNA and Mr. Dekel Gelbman, FDNA’s CEO.
“We are excited to showcase our technology at this prestigious venue. After years of developing and validating this innovative technology with the help of our trusted partners, it is only natural that we would give something back and make our solutions available for free to the entire genetic community,” said Mr. Dekel Gelbman, FDNA's Chief Executive Officer.
FDNA's mission is to save lives and improve the quality of life of patients with rare or difficult-to-diagnose genetic syndromes. FDNA has developed the proprietary Facial Dysmorphology Novel Analysis technology. This cutting-edge technology facilitates comprehensive analyses of dysmorphic features and recognizable patterns of human malformations from facial photos.
Using advanced learning algorithms, the technology improves over time, referencing comprehensive phenotype databases in real-time.
Using the power of cloud-computing and a HIPAA compliant community platform, FDNA brings this innovation to mobile devices. FDNA’s solutions aid and empower in accelerating and increasing confidence in the research and investigation of genetic syndromes while leveraging the ever-increasing amounts of data in human genetics and dysmorphology.
Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/03/prweb11667032.htm